Move expected to generate significant cost savingsMOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for ...

Core Insights - Iridex Corporation demonstrated continued revenue growth, operational efficiencies, and positive cash flow in its preliminary unaudited results for Q4 and full year 2025 [1][4] Fourth Quarter 2025 Results - Total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter [8] - The company achieved positive cash flow in the fourth quarter [8] - Sold 15,800 Cyclo G6 probes, an increase from 13,300 in the prior year quarter [8] - Sold 44 Cyclo G6 Glaucoma Laser Systems, slightly down from 47 in the prior year quarter [8] Full Year 2025 Results - Total revenue is expected to be between $52.5 million and $52.7 million, reflecting year-over-year growth of 8% compared to $48.7 million in 2024 [8] - The company expects to achieve positive adjusted EBITDA for the full year 2025 [8] - Sold 57,700 Cyclo G6 probes, an increase from 55,400 in the prior year [8] - Sold 133 Cyclo G6 Glaucoma Laser Systems, up from 125 in the prior year [8] Company Overview - Iridex Corporation is a leader in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market [5] - The company's proprietary MicroPulse technology offers safe and effective treatment for sight-threatening eye conditions [5]

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].